这项研究的目的是描述临床发现,诊断测试结果和对Schirmer撕裂测试1(STT-1)值低于参考区间的猫的治疗反应。
在三个机构的医疗记录中搜索患有眼表疾病且STT-1值<9mm/min的猫,在两次或两次以上的单独访问中确认。
包括10只猫(17只眼)。受累眼的平均±SD(范围)年龄和STT-1值分别为6.1±5.7(0.2-16)岁和2.4±3.1(0-8)mm/min,分别。5/10猫的并发眼表疾病为双侧。临床体征包括结膜炎(14/17眼),角膜溃疡(6/17眼),非溃疡性角膜炎(4/17眼),symblepharon(4/17眼),嗜酸性角膜炎(3/17眼),角膜后遗症(3/17眼),角膜纤维化(2/17眼)和睑板膜炎(2/17眼)。管理包括:局部应用泪模,抗病毒药物,皮质类固醇或免疫调节药物;口服泛昔洛韦;或外科手术,在各种组合中。对治疗的反应(定义为STT-1值增加5mm/min)在65%的眼睛中是短暂的(在一次重新评估中看到),在18%的眼睛中是持续的(在2次连续重新评估中看到)。
描述了在STT-1值低的猫中看到的临床特征,尽管目前尚不清楚房水缺乏与所报道的眼部变化之间的关联。我们鼓励临床医生评估眼表疾病猫的泪膜,如果STT-1值反复低于正常,则开始使用泪模药物治疗。这些信息将进一步定义猫的泪液缺乏,提供对疾病患病率的更好了解,发病机制和治疗。
The aim of this study was to describe the clinical findings, diagnostic test results and response to therapy of cats with Schirmer tear test 1 (STT-1) values below the reference interval.
The medical records of three institutions were searched for cats with ocular surface disease and STT-1 values <9 mm/min, confirmed at two or more separate visits.
Ten cats (17 eyes) were included. The mean ± SD (range) age and STT-1 values in affected eye(s) were 6.1 ± 5.7 (0.2-16) years and 2.4 ± 3.1 (0-8) mm/min, respectively. Concurrent ocular surface disease was bilateral in 5/10 cats. Clinical signs included conjunctivitis (14/17 eyes), corneal ulceration (6/17 eyes), non-ulcerative keratitis (4/17 eyes), symblepharon (4/17 eyes), eosinophilic keratitis (3/17 eyes), corneal sequestrum (3/17 eyes), corneal fibrosis (2/17 eyes) and meibomitis (2/17 eyes). Management included: topically applied lacrimomimetics, antiviral drugs, corticosteroids or immunomodulatory drugs; orally administered famciclovir; or surgical procedures, in various combinations. Response to therapy (defined as an increase in STT-1 value of ⩾5 mm/min) was transient (seen at a single reassessment) in 65% of eyes and sustained (seen at ⩾2 consecutive reassessments) in 18% of eyes.
Clinical features seen in cats with low STT-1 values are described, although the association between aqueous deficiency and the reported ocular changes is unknown at this time. We encourage clinicians to assess the tear film in cats with ocular surface disease, and initiate therapy with lacrimomimetics if STT-1 values are repeatedly below normal. Such information will further define aqueous tear deficiency in cats, providing a better understanding of disease prevalence, pathogenesis and treatment.